ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium

References

• Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411–424.
   PubMed Web of Science ®Google Scholar
• George A, Kaye S, Banerjee S, et al. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–296.
   PubMed Web of Science ®Google Scholar
• Gelmo A, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–2505.
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–327.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
   PubMed Web of Science ®Google Scholar
• Pilié PG, Gay CM, Byers LA, et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019 1;25(13):3759–3771.
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A, et al. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–819.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–120.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115.
   PubMed Web of Science ®Google Scholar
• Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9:3970.
   PubMed Web of Science ®Google Scholar
• Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced ‘BRCAness’ and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479.
   Web of Science ®Google Scholar
• Olaussen KA, Adam J, Vanhecke E, et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer (Amst Neth). 2013;80:216–222.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer (Amst Neth). 2010;70:63–70.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34:739–749.
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73:2271–2280.
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:2728–2737.
   PubMed Web of Science ®Google Scholar
• Tuli R, Surmack AJ, Reyes J, et al. Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888. Transl. Oncol. 2014;7:439–445.
   Web of Science ®Google Scholar
• Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:7277–7290.
   PubMed Web of Science ®Google Scholar
• Pahuja S, Beumer JH, Appleman LJ, et al. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol. 2015;33:1015.
   PubMedGoogle Scholar
• Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:2705–2711.
   PubMed Web of Science ®Google Scholar
• Mizugaki H, Yamamoto M, Nokihara H, et al. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2015;76:1063–1072.
   PubMed Web of Science ®Google Scholar
• McKee MD, Bondarenko I, Guclu SZ, et al. Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial. J Clin Oncol. 2015;33(15_suppl). Available at https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8107
   Google Scholar
• Ramalinga S, Blais N, Mazieres J, et al. Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:1937–1944.
   PubMed Web of Science ®Google Scholar
• Reck M, Blais N, Juhasz E, et al. Smoking history predicts sensitivity to PARP inhibitor veliparib in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:1098–1108.
   PubMed Web of Science ®Google Scholar
• Cristea MC, Miao J, Argiris A, et al. SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(15_suppl). doi:10.1200/JCO.2016.34.15_suppl.8537
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dai H, Li Y, et al. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer. 2019;144:1092–1103.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3543–3551.
   PubMed Web of Science ®Google Scholar
• Novello S, Besse B, Felipe E, et al. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:2156–2162.
   PubMed Web of Science ®Google Scholar
• Deben C, Lardon F, Wouters A, et al. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Lett. 2016;375:313–322.
   PubMed Web of Science ®Google Scholar
• Campelo RG, Arrieta Rodriguez OG, Massuti B, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group). J Clin Oncol. 2018;36(15_supp) doi:10.1200/JCO.2018.36.15_suppl.9012
   Web of Science ®Google Scholar
• Hirai T, Saito S, Fujimori H, et al. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochem Biophys Res Commun. 2016;478:234–240.
   PubMed Web of Science ®Google Scholar
• Senra JM, Telfer BA, Cherry KE, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10:1949–1958.
   PubMed Web of Science ®Google Scholar
• Lesueur P, Chevalier F, Austry JB, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8:69105–69124.
   PubMedGoogle Scholar
• Jiang Y, Verbiest T, Devery AM, et al. Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality. Int J Radiat Oncol Biol Phys. 2016;95:772–781.
   PubMed Web of Science ®Google Scholar
• Mehta MP, Wang D, Wang F, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol. 2015;122:409–417.
   PubMed Web of Science ®Google Scholar
• Chabot P, Hsia TC, Ryu JS, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol. 2017;131:105–115.
   PubMed Web of Science ®Google Scholar
• George A, Banerjee S, Kaye S, et al. Olaparib and somatic BRCA mutations. Oncotarget. 2017 4;8(27):43598–43599.
   PubMedGoogle Scholar
• A study evaluating the efficacy and tolerability of veliparib in combination with paclitaxel/carboplatin-based chemoradiotherapy followed by veliparib and paclitaxel/carboplatin consolidation in subjects with stage III non-small cell lung cancer - Full text view - ClinicalTrials.gov. [cited 2019 Aug 12th]. Available at https://clinicaltrials.gov/ct2/show/NCT02412371
   Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:3711–3720.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141.
   Web of Science ®Google Scholar
• Konecny GE, Oza AM, Tinker AV, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecol Oncol. 2017;145(S1):2.
   Web of Science ®Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;137:386–391.
   PubMed Web of Science ®Google Scholar
• Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147:267–275.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140:199–203.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882–892.
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152:243–250.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1080–1087.
   Google Scholar
• Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol. [cited 2019 Jul 29th]. doi:10.1200/JCO.2016.34.15_suppl.5533
   Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 1;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:397–404.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–13598.
   PubMed Web of Science ®Google Scholar
• Wieser V, Gaugg I, Fleischer M, et al. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget. 2018;9:17501–17511.
   PubMedGoogle Scholar
• Abstract P4-04-01. PDL-1 expression in primary breast cancers with germline mutations in BRCA 1 and 2. Cancer Res. [cited 2019 Jul 29th]. Available at http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-04-01
   Web of Science ®Google Scholar
• ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC). 2019 ASCO Annual Meeting Abstracts. [cited 2019 Jul 28]. Available at https://abstracts.asco.org/239/AbstView_239_269271.html
   Google Scholar
• Study of pembrolizumab with maintenance olaparib or maintenance pemetrexed in first-line (1L) metastatic nonsquamous non-small-cell lung cancer (NSCLC) (MK-7339-006, KEYLYNK-006) - Full text view - ClinicalTrials.gov. [cited 2019 Aug 12]. Available at https://clinicaltrials.gov/ct2/show/NCT03976323
   Google Scholar
• A study of pembrolizumab (MK-3475) with or without maintenance olaparib in first-line metastatic squamous non-small cell lung cancer (NSCLC, MK-7339-008/KEYLYNK-008) - Full text view - ClinicalTrials.gov. [cited 2019 Aug 12]. Available at https://clinicaltrials.gov/ct2/show/NCT03976362
   Google Scholar
• Rucaparib and pembrolizumab for maintenance therapy in stage IV non-squamous non-small cell lung cancer - Full text view - ClinicalTrials.gov. [cited 2019 Aug 12]. Available at https://clinicaltrials.gov/ct2/show/NCT03559049
   Google Scholar
• Study of veliparib in combination with nivolumab and platinum doublet chemotherapy in participants with metastatic or advanced non-small cell lung cancer (NSCLC) - Full text view - ClinicalTrials.gov. [cited 2019 Aug 12]. Available at https://clinicaltrials.gov/ct2/show/NCT02944396
   Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 27;489(7417):519–525.
   PubMed Web of Science ®Google Scholar
• Hendriks LE, Rouleau E, Besse B, et al. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Transl Lung Cancer Res. 2018;7:647–660.
   Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim HS, Kim BJ, et al. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Oncotarget. 2017;8(54):93149-93155.
   Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
   PubMed Web of Science ®Google Scholar